Vtv Therapeutics Inc.

  • Moat Score
  • Market Cap $NaN
  • PE -
  • Debt $0.00
  • Cash $41.57M
  • EV $NaN
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$22.71M
EBIT-$22.88M
ROE-127%
ROA-53%
Equity$17.91M
Growth Stability1
Debt/Equity0
Net Margins-2K%
Op. Margins-2K%
Sales CAGR-7%
Earnings Growth YoY-32%
Earnings Growth QoQ-9%
Sales CAGR 5Y-30%
Earnings CAGR 3Y-61%
Sales CAGR 3Y-61%
Revenue$1.00M
Assets$43.16M
Total Debt$0.00
Cash$41.57M
Moat Score0%
Working Capital36.53M
Current Ratio6.69
Equity Growth QoQ-12%
Equity Growth YoY-171%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

SEC Filings

Direct access to Vtv Therapeutics Inc. (VTVT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Vtv Therapeutics Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vtv Therapeutics Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vtv Therapeutics Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vtv Therapeutics Inc..

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-2K%-8K%-9K%-19K%-192%-794%-200%-443%-1K%--2K%
ROA--42%-101%-182%-232%-225%-80%-69%-68%-231%-53%
ROE-53%61%36%29%45%16%182%233%105%-127%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF---0.26-0.54-0.91-0.49-0-0.01-0.01-0.01-
Debt over Equity-0--0.14-0.16-0.3-0.23-0-0.03-0.02-0.010
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--66%22%-54%4K%-78%132%-38%-50%-100%-30%
Earnings YoY growth-14%35%-1%-56%-8%-42%39%41%4%-
Equity YoY growth--84%17%66%-45%-41%63%-88%10%130%-
FCF YoY growth-20%30%-8%-40%-14%-22%7%-17%19%-